Moderna, Inc. Q4 2025 Earnings Call Summary

Core Insights - The company achieved a significant financial turning point in 2025 by reducing operating expenses by $2.2 billion, exceeding original cost-reduction targets by over $1 billion [1] - Revenue performance in 2025 was attributed to the successful U.S. launch of MNEXT Spike, which captured 24% of the total retail market despite a decline in overall COVID demand [1] - The company expressed strong disappointment with the FDA's Refusal to File letter for the mRNA-1010 flu vaccine, citing unpredictable regulatory environments as a threat to U.S. innovation leadership [1] Strategic Focus - The company shifted its strategic focus toward long-term sovereign partnerships in the U.K., Canada, and Australia to provide stable, annualized revenue streams starting in 2026 [1] - The oncology narrative was advanced by completing enrollment in three late-stage INT studies (melanoma, renal cell, and bladder cancer), reinforcing the platform's multi-histology potential [1] Operational Efficiency - The company leveraged AI integration across the business to drive productivity while maintaining a disciplined $1.0 billion SG&A spend and expanding into new geographic markets [1]